Resverlogix Corp. is a Canada-based, clinical stage cardiovascular company. The Company has pigenetic platform technology that modulates protein production. The Company is engaged in developing RVX-208, a small molecule for the treatment of atherosclerosis. RVX-208 is a first bromodomain and extra terminal domain (BET) inhibitor in clinical trials. New compounds arising from the Company's epigenetic drug development platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases, including neurodegenerative diseases and diabetes mellitus. Its clinical cardiovascular programs include cardiovascular disease and atherosclerosis, Apoa-I, HDL and reverse cholesterol transport, and RVX-208 and MOA.